RECRUITING

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Talk to us

Conditions

Rare CancersCholangiocarcinomaCancer of Unknown Primary Sitegenomicsprecision medicinemolecular tumor boardremote participationtargeted therapypatient reported outcomesunderstudied diseasescomprehensive genomic profilingvirtualnext generation sequencingliquid biopsiestumor biopsiescell-free DNAbiomarker testingsolid tumors

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Official Title

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Quick Facts

Study Start:2020-10-01
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04504604

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Mary Oster
CONTACT
617-299-0389
track@targetcancerfoundation.org

Principal Investigator

Razelle Kurzrock, M.D.
PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Vivek Subbiah, M.D.
PRINCIPAL_INVESTIGATOR
SCRI Development Innovations, LLC
Shumei Kato, M.D.
PRINCIPAL_INVESTIGATOR
University of California, San Diego

Study Locations (Sites)

TargetCancer Foundation
Cambridge, Massachusetts, 02139
United States

Collaborators and Investigators

Sponsor: TargetCancer Foundation

  • Razelle Kurzrock, M.D., PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin
  • Vivek Subbiah, M.D., PRINCIPAL_INVESTIGATOR, SCRI Development Innovations, LLC
  • Shumei Kato, M.D., PRINCIPAL_INVESTIGATOR, University of California, San Diego

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-10-01
Study Completion Date2025-12

Study Record Updates

Study Start Date2020-10-01
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • genomics
  • precision medicine
  • molecular tumor board
  • remote participation
  • targeted therapy
  • patient reported outcomes
  • understudied diseases
  • comprehensive genomic profiling
  • virtual
  • next generation sequencing
  • liquid biopsies
  • tumor biopsies
  • cell-free DNA
  • biomarker testing
  • solid tumors

Additional Relevant MeSH Terms

  • Rare Cancers
  • Cholangiocarcinoma
  • Cancer of Unknown Primary Site